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NeTosis in Alzheimer’s Disease
Enrica Caterina Pietronigro, Vittorina Della Bianca, Elena Zenaro and Gabriela Constantin*
Department of Medicine, Section of General Pathology, University of Verona, Verona, Italy
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the progressive 
deterioration of cognitive functions. Its neuropathological features include amyloid-β 
(Aβ) accumulation, the formation of neurofibrillary tangles, and the loss of neurons 
and synapses. Neuroinflammation is a well-established feature of AD pathogenesis, 
and a better understanding of its mechanisms could facilitate the development of 
new therapeutic approaches. Recent studies in transgenic mouse models of AD have 
shown that neutrophils adhere to blood vessels and migrate inside the parenchyma. 
Moreover, studies in human AD subjects have also shown that neutrophils adhere 
and spread inside brain vessels and invade the parenchyma, suggesting these cells 
play a role in AD pathogenesis. Indeed, neutrophil depletion and the therapeutic 
inhibition of neutrophil trafficking, achieved by blocking LFA-1 integrin in AD mouse 
models, significantly reduced memory loss and the neuropathological features of 
AD. We observed that neutrophils release neutrophil extracellular traps (NETs) inside 
blood vessels and in the parenchyma of AD mice, potentially harming the blood–brain 
barrier and neural cells. Furthermore, confocal microscopy confirmed the presence of 
NETs inside the cortical vessels and parenchyma of subjects with AD, providing more 
evidence that neutrophils and NETs play a role in AD-related tissue destruction. The 
discovery of NETs inside the AD brain suggests that these formations may exacerbate 
neuro-inflammatory processes, promoting vascular and parenchymal damage during 
AD. The inhibition of NET formation has achieved therapeutic benefits in several models 
of chronic inflammatory diseases, including autoimmune diseases affecting the brain. 
Therefore, the targeting of NETs may delay AD pathogenesis and offer a novel approach 
for the treatment of this increasingly prevalent disease.
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iNTRODUCTiON
The formation of neutrophil extracellular traps (NETs) is a defense mechanism used by neutro-
phils to trap and efficiently limit the damage caused by a wide range of microbial targets (1). NET 
production is associated with dramatic changes in cellular morphology, including the extrusion 
of decondensed chromatin into the extracellular space to form web-like structures decorated with 
histones and granular antimicrobial proteins, such as neutrophil elastase (NE), myeloperoxidase 
(MPO), proteinase 3, cathepsin G, lactoferrin, matrix metalloproteinase 9 (MMP-9), peptidoglycan-
recognition proteins, pentraxin, and LL-37 (1–4). The sequential molecular events that generate 
NETs are the production of reactive oxygen species (ROS), the migration of NE protease and later 
MPO from granules to the nucleus, the processing of histones, and the rupture of the cell (5). NETs 
provide a key defense mechanism against pathogens to prevent their systemic dissemination dur-
ing infection (1, 6). However, NETs are also major effectors involved during sterile inflammation, 
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autoimmune diseases, such as systemic lupus erythematosus 
(SLE), and atherosclerosis, and they may also promote metastasis 
(1, 7). In addition, we have recently shown the release of NETs in 
Alzheimer’s disease (AD), suggesting that NETs may also play a 
role in AD pathology (8).
Alzheimer’s disease, one of the most devastating neurode-
generative disorders, is characterized by progressive memory 
decline and cognitive deficits. The main neuropathological 
features of AD include neuritic plaques formed by deposits of 
amyloid-β (Aβ), the abnormal accumulation of hyper-phos-
phorylated tau protein in the neuronal soma, which manifests 
as neurofibrillary tangles (NFTs), synaptic dysfunction, and 
neuronal loss (9). AD is also characterized by cerebral amyloid 
angiopathy due to Aβ deposits in the cerebral vasculature, 
which lead to luminal stenosis, endothelial damage, basement 
membrane thickening, thrombosis, loss of autoregulation, and 
vasospasm (10). Chronic neuroinflammation is thought to 
play a role in AD pathology, and recent studies have identified 
several inflammation pathway genes associated with the risk 
of AD (11, 12). Microglial activation precedes neuronal loss 
in AD patients, and microglia-mediated neuro-inflammatory 
responses may promote the neurodegeneration observed in AD 
(9, 13). Moreover, in response to Aβ or NFTs, microglial cells 
produce pro-inflammatory cytokines, chemokines, and comple-
ment peptides, which can amplify the neuroinflammation in 
AD (13). Aβ and tau deposits cause detrimental effects in the 
neuronal milieu, due to the excessive release of cytotoxic factors, 
including the interleukins IL-1β and IL-6, tumor necrosis factor 
α (TNFα), and free radicals, enhancing neuroinflammation and 
neuronal damage (8, 11–14). Epidemiological studies indicate 
that non-steroidal anti-inflammatory drugs (NSAIDs) reduce 
the risk of AD, providing further evidence that inflammation 
mechanisms play a role in this disease (15, 16). However, the lack 
of efficacy of NSAIDs against AD in clinical trials suggests that 
more specific inflammation mechanisms must be identified to 
inhibit AD-related neuroinflammation (11, 16, 17).
Compelling evidence indicates that AD-related inflammation 
develops in two different but interconnected compartments: the 
blood and the brain. In this context, systemic inflammation can 
lead to “brain activation,” whereas cerebral inflammation may 
in turn influence the peripheral system through the release of 
danger signals and other inflammatory mediators (12, 18–21). 
The blood–brain barrier (BBB) is a connection point between 
blood and circulating leukocytes on one side and the brain 
parenchyma on the other. It is a highly specialized endothelial 
cell membrane that regulates the passage of essential nutrients 
and leukocytes into the central nervous system (CNS) and 
facilitates the clearance of potentially neurotoxic molecules 
from the brain to the blood (18–21). The BBB together with 
vascular cells (pericytes and vascular smooth muscle cells), glial 
cells, and neurons, constitutes the neurovascular unit (NVU) 
(20, 21). AD is characterized by the loss of BBB integrity, which 
disrupts the clearance of Aβ and thus promotes Aβ accumulation 
in the brain, leading to neuronal injury and cognitive decline 
(20). The accumulation of Aβ in the brain and in the vessel walls 
also induces the expression of adhesion molecules on brain 
endothelial cells and the release of inflammatory mediators, such 
as cytokines, chemokines, and complement system peptides, 
potentially facilitating the adhesion and subsequent transmigra-
tion of leukocytes. Previous studies have shown that tau may also 
contribute to BBB deterioration in vitro, and BBB dysfunction 
correlates with the appearance of perivascular tau around major 
hippocampal blood vessels in  vivo (22–24). Both tau and Aβ 
may, therefore, induce BBB dysfunction, contributing to brain 
inflammation and neurodegeneration.
The role of circulating immune system cells in AD has not 
been investigated in detail, but the migration of cells related to 
both innate and adaptive immunity has been observed in the 
AD brain (21, 25, 26). For example, monocytes migrate through 
the brain endothelium into the AD brain in a CCR2-dependent 
manner, and previous studies suggest they may promote Aβ 
clearance (27). However, the replacement of brain-resident 
myeloid cells with circulating peripheral monocytes in AD 
mouse models showed that monocyte repopulation does not 
modify the amyloid load, challenging the idea that peripheral 
monocytes play a role in Aβ clearance (28, 29). Lymphocytes can 
also enter the AD brain, and both CD4+ and CD8+ T cells in AD 
patients were shown to adhere inside the cerebral blood vessels 
or to migrate into the parenchyma (21, 26). Nevertheless, the role 
of these cells remains unclear because recent studies indicate they 
may play either a positive or negative role in AD models, prob-
ably depending on the specific cell subset and disease phase (21, 
26). Unexpectedly, neutrophils were also found inside the brain 
vessels and parenchyma of AD subjects, and the capacity of neu-
trophils to invade the AD brain has recently been confirmed (8, 
30–32). Moreover, our recent data reveal that neutrophils adhere 
to blood vessels and infiltrate inside the brain parenchyma in two 
transgenic animal models of AD, inducing cognitive deficit and 
neuropathological changes (8). Neutrophil depletion reduced 
the neuropathological hallmarks of AD and improved memory 
functions in these models, suggesting that neutrophils play a key 
role in AD pathogenesis (8).
Recently, we have observed NETs within the cerebral vascu-
lature and parenchyma of animal AD models and individuals 
with AD, suggesting that NETs can potentially harm the BBB 
and neural cells (8). In this review, we discuss the involvement 
of NETs in AD as a novel mechanism for neutrophil-mediated 
neurotoxicity and neurodegeneration and suggest that the inhibi-
tion of NETs may offer a new pharmacological approach to slow 
down the progression of this disease.
NeUTROPHiLS iN AD
Circulating neutrophils are the most abundant leukocytes in 
the peripheral blood and they provide the first line of defense 
in the innate immune system. Neutrophils are short-lived cells 
with circulating half-lives of approximately 1.5  h in mice and 
8 h in humans, although this was recently challenged and longer 
survival times of up to several days were reported in humans 
(1). Nevertheless, neutrophils are activated during inflammation 
and their longevity increases, allowing them to carry out more 
complex activities, potentially causing bystander cell injury. 
Neutrophils are thought to be the main protagonists in the first 
line of defense during acute inflammation, when many of these 
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cells migrate into tissues and can easily be identified using conven-
tional histology techniques. However, neutrophils have attracted 
more attention recently in the context of chronic inflammation, 
e.g., atherosclerosis, rheumatoid arthritis, SLE, anti-neutrophil 
cytoplasmic antibody-related vasculitis, deep vein thrombosis, 
chronic obstructive pulmonary disease, cystic fibrosis, and ani-
mal models of multiple sclerosis (33–35). Neutrophils are now 
thought to be key players that directly affect the pathogenesis of 
chronic inflammatory diseases. For example, they were recently 
shown to play a prominent role in chronic low-grade adipose 
tissue inflammation and insulin resistance mediated by the secre-
tion of elastase (36, 37).
Neutrophil recruitment in the CNS is a central process dur-
ing the pathogenesis of several neuro-inflammatory disorders, 
ranging from bacterial and viral encephalitis to non-infectious 
conditions, such as cerebral ischemia, trauma, and demyelinating 
syndromes (25, 35, 38, 39). Previous studies have shown that neu-
trophils transmigrated in the CNS acquire a toxic phenotype and 
approach neuronal cells, where they release harmful molecules 
and can compromise neuronal functions (40). Therefore, limiting 
neutrophil migration and/or functions can positively influence 
the outcome of neuronal injuries (8, 21, 35, 39).
The first evidence that neutrophils accumulate in the CNS of 
AD patients was the detection of cells expressing the neutrophil-
specific protease cathepsin G within the AD brain parenchyma 
and cerebral blood vessels, often associated with Aβ deposits 
(30). This was followed by the detection of CAP37, an inflam-
matory mediator constitutively expressed in neutrophils, in the 
cerebral microvasculature of AD patients but not in age-matched 
controls or patients with other neuropathological conditions, 
such as Pick’s disease, Parkinson’s disease, Binswanger’s disease, 
or supranuclear palsy (31, 41). Initially, the expression of CAP37 
in the AD brain was not linked with the presence of neutro-
phils, but was instead associated with endothelial activation 
and neuronal cells, and was thought to be induced by Aβ (31, 
41, 42). More recently, we identified MPO+ cells in areas with 
Aβ deposits, further supporting the presence of neutrophils in 
the AD brain (8). We found that intraparenchymal MPO+ cells 
were mainly localized to within 50 μm of Aβ plaques, and their 
distribution was non-random, suggesting that Aβ may act as 
a chemoattractant by creating a favorable microenvironment 
for the accumulation of neutrophils inside the brain, thus 
promoting their pro-inflammatory activities (8). We also used 
(i) hematoxylin and eosin staining to confirm the presence of 
polysegmented nuclei in cells that have migrated perivascularly 
or within the parenchyma (8), (ii) napthol AS-D chloroacetate 
esterase staining in brain sections to confirm the presence of 
cells of the granulocytic lineage specifically in AD brains (43, 
44), and (iii) staining for the neutrophil-specific marker, CD66b, 
which likewise confirmed that neutrophils were present specifi-
cally in the brains of AD subjects but not age-matched controls 
(8). These neuropathological studies are supported by recent 
clinical data revealing increased numbers of neutrophils or a 
higher neutrophil/lymphocyte ratio associated with AD, sug-
gesting that changes in the neutrophil population could be used 
as markers of AD-related peripheral inflammation (45–47). 
The amyloid protein precursor (APP) is also expressed more 
strongly in the granulocytes of AD patients compared to con-
trols, whereas there was no statistically significant difference in 
the lymphocyte and mononuclear cell populations, suggesting 
that the strong expression of APP in peripheral mononuclear 
cells could be used for the early diagnosis of AD (48). Other 
studies have also revealed differences in neutrophil functions 
and changes in granulocyte density in AD patients, further sug-
gesting that the analysis of blood neutrophils may offer new AD 
biomarkers (49, 50).
In agreement with the data from AD subjects, we have recently 
shown the presence of Gr-1+ cells in 3xTg-AD mice during the 
early phases of AD, and more recent data obtained in the 5xFAD 
transgenic AD model revealed Gr1+ cells infiltrating the brain 
parenchyma and migrating toward Aβ plaques (32, 51). Our data 
in 5xFAD and 3xTg-AD mice confirmed these results, showing 
infiltrating neutrophils within the brain parenchyma at the onset 
of memory deficit, especially in the cortex and hippocampus, 
highlighting the role of these cells in AD pathogenesis (8). In 
addition, our two-photon laser-scanning microscopy (TPLSM) 
studies revealed neutrophil extravasation inside the cerebral 
parenchyma during the early phases of AD, preferentially in 
zones adjacent to vascular and intraparenchymal Aβ deposits, 
suggesting that Aβ may play an important role in neutrophil 
recruitment and movement inside the brain parenchyma (8). As 
stated above, Aβ may act as a chemoattractant for neutrophils 
and may represent an FPR1-binding “end-target” chemoat-
tractant prevailing over “intermediate” chemokines, potentially 
contributing to the directional bias observed for a significant 
proportion of extravasated neutrophils in the brains of AD 
mouse models (8, 52, 53). FPR1 and LFA-1 may, therefore, 
promote neutrophil deep tissue penetration and thus contribute 
to widespread tissue damage.
In our studies, LFA-1 integrin controlled not only the 
intraparenchymal motility of extravasated neutrophils but 
also their intravascular adhesion in the cerebral microcircula-
tion of transgenic AD mice (8). By blocking LFA-1 integrin in 
AD mice during the early phases of AD, neutrophil adhesion 
and extravasation were prevented and the neuropathological 
hallmarks of AD were clearly reduced, thus restoring cogni-
tive functions. Notably, a transient therapeutic blockade of 
LFA-1 integrin during the early stages of disease also provided 
a long-term beneficial effect on cognition in older mice, sug-
gesting that the therapeutic reduction of neutrophil trafficking 
during the early phases of AD may have prolonged beneficial 
effects in AD patients. Moreover, 3xTg-AD mice lacking LFA-1 
integrin showed improved memory functions in behavioral 
tests compared to wild-type control mice, and the severity of 
microgliosis was reduced (8). The role of neutrophils in AD 
has been defined only recently, so the mechanisms controlling 
neutrophil trafficking and interactions with CNS-resident cells 
must be investigated in more detail.
In vivo experiments have shown that fluorescence-labeled 
neutrophils start to infiltrate the brain parenchyma of 5xFAD 
mice 12–18 h after cell injection, continue to migrate and reach 
a peak at 24 h post-injection, and then become undetectable at 
48  h post-injection, suggesting that the half-life of the migrat-
ing neutrophils in the brain is approximately 12 h. Neutrophils 
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are highly reactive cells, releasing ROS, enzymes, NETs, and 
cytokines, and can thus cause chronic collateral tissue damage 
even in the absence of substantial accumulation within tissues 
during low-grade chronic sterile inflammation. Furthermore, 
previous results from our group and others have shown that neu-
trophils do not necessarily need to accumulate in high numbers 
in order to induce tissue damage: intravascular adhesion per se 
without transmigration is sufficient to induce endothelial injury 
and the resulting tissue damage (54, 55). This is supported by our 
data showing that blocking LFA-1 integrin, which controls the 
intravascular adhesion of neutrophils, reduces cognitive damage 
and neuropathological lesions in AD models. Our recent results 
also demonstrate that transgenic AD mouse models treated 
with a neutrophil-depleting antibody show a reduction in both 
microglial cell density and their activation state, suggesting 
that neutrophils promote the activation of glial cells, fueling 
an inflammatory loop that may promote neuronal injury and 
memory decline (8).
iNTRAvASCULAR NeTs iN AD
The release of intravascular NETs by adherent neutrophils has 
been observed in several diseases, including sepsis, atherosclero-
sis, autoimmune pathologies, such as autoimmune small-vessel 
vasculitis, experimental deep vein thrombosis, transfusion-related 
acute lung injury, and cancer (1, 4, 56–59). Intravascular NETosis 
can be triggered by different stimuli including microbes, pro-
inflammatory cytokines, activated platelets, and antibody–anti-
gen complexes (1, 2, 56, 60, 61).
The intravascular neutrophil adhesion cascade that causes 
neutrophils to leave the blood circulation begins with the 
capture of these cells on the endothelium followed by their 
rolling and firm arrest on activated endothelial cells (1, 25). 
Adhesion receptors specialized for the arrest of intravascular 
neutrophils are heterodimeric transmembrane proteins known 
as integrins. In order to mediate firm adhesion, integrins 
undergo an activation process induced by chemoattractants via 
G-protein-coupled receptors. The activation of the intracellular 
pathways leading to increased ligand binding affinity (“integrin 
activation”) and the clustering of integrins in the membrane, 
which together allow cell attachment, is defined as “inside–out 
signaling” (62). Furthermore, the signaling steps that occur 
following the ligand-induced clustering of leukocyte integrins 
are described as the “outside–in pathway” (62). Indeed, β2 
integrin engagement stabilizes neutrophil adhesion to the 
inflamed endothelium and induces neutrophils to release ROS, 
cytotoxic enzymes, arachidonic acid derivatives, cytokines, and 
chemoattractants, which may have a detrimental effect on the 
vessel wall (53, 55). Previous studies including our own have 
also shown that neutrophil adhesion on the vessel wall without 
transmigration is sufficient to induce endothelial injury, sug-
gesting that intravascular adhesion per  se may trigger NET 
formation and consequent endothelial injury, compromising 
BBB integrity (54, 55, 63). The adhesion-dependent production 
of ROS may also trigger the machinery involved in the final 
extrusion of fibers containing DNA and granule proteins (5). 
The adhesion of neutrophils to the endothelium induced by the 
engagement of αMβ2 integrin (Mac-1) promotes the release of 
NETs by neutrophils in the presence of lipopolysaccharide (64). 
In addition, the activation of αMβ2 integrin induces changes 
in the neutrophil cytoskeleton that facilitate the breakdown of 
nuclear and plasma membranes, favoring the release of NETs 
(64). The engagement of LFA-1, another β2 integrin (αLβ2 
heterodimer) expressed by neutrophils, triggers NET formation 
by activated platelets in vitro and in vivo (Figure 1) (59). During 
inflammation, Mac-1 and LFA-1 mediate interactions with 
vascular ICAM-1, and microvascular endothelial cells produce 
higher levels of ICAM-1 in both transgenic AD mouse models 
and human AD patients (8, 25). Interestingly, we have recently 
reported the expression of adhesion molecules in areas bur-
dened by Aβ plaques and rich in migrated leukocytes in animal 
models of AD (8). Accordingly, in  vitro studies have demon-
strated that Aβ peptides induce the expression of endothelial 
adhesion molecules, including ICAM-1 in mouse and human 
brain endothelial cells, suggesting that Aβ may play a role in 
endothelial activation and intravascular neutrophil adhesion 
in AD (8, 65). Our recent data indicate that both oligomeric 
and fibrillary Aβ1–42 trigger the rapid, integrin-dependent 
adhesion of human and mouse neutrophils on fibrinogen and 
ICAM-1, a ligand for LFA-1 integrin (8). Moreover, we have 
shown that Aβ1–42 induces both the intermediate-affinity 
and high-affinity states of LFA-1, potentially providing stop 
signals for neutrophils. In addition, our recent data indicate 
that neutrophils migrate into the brains of AD mouse models 
by engaging LFA-1 integrin and that blocking this β2 integrin 
prevents neutrophil adhesion in cortical venules and subsequent 
extravasation, suggesting intravascular neutrophil adhesion 
through β2 integrins may trigger the formation of NETs in 
AD (8). We also have recently confirmed the formation of intra-
vascular NETs in 5xFAD and 3xTg-AD mice and proposed as a 
mechanism for neutrophil-dependent damage in AD (Figure 1) 
(8). Furthermore, we have documented intravascular neutrophil 
adhesion and the release of NETs in the brains of human AD 
subjects, suggesting that intravascular NETs may also contribute 
to CNS damage in humans.
Previous studies have shown that pro-inflammatory 
cytokines, such TNFα, IL-1β, and IL-8, can be released by acti-
vated endothelial cells and may, therefore, trigger intravascular 
NETs (60, 66–68). The cerebral vasculature in human AD sub-
jects is strongly activated and produces cytokines, suggesting 
that intravascular cytokines may favor the formation of NETs in 
this context. AD brain microvessels release significantly higher 
levels of thrombin, TNFα, IL-1β, and IL-8 than age-matched 
controls, indicating that such endothelial molecules may pro-
mote the formation of NETs by adherent neutrophils (69–71). 
Thrombin in particular becomes more abundant in the cerebral 
capillaries of AD brains, and induces the release of IL-1β and 
IL-8, which may in turn contribute to intravascular NETosis (60, 
70–73). Interestingly, subjects with mild cognitive impairment 
have higher serum IL-1β levels than controls, suggesting this 
cytokine may trigger the release of NETs and contribute to the 
onset of AD (74). Previous studies have also shown elevated 
levels of IL-1β and TNFα in the serum of AD patients (74–76). 
In vitro studies of brain endothelial cells indicate that exposure 
FigURe 1 | Potential deleterious effects of neutrophil extracellular traps (NeTs) in Alzheimer’s disease (AD). Aβ and other DAMPs and pro-inflammatory 
factors lead to the activation of cerebral endothelial cells, inducing the upregulation of adhesion molecules and chemoattractants on these cells. This allows 
circulating neutrophils to adhere intravascularly via LFA-1 β2 integrin–ICAM-1 binding and then extravasate into the brain. Chemoattractants on the surface of the 
endothelium may activate β2 integrins via inside–out signaling triggered by G-protein-coupled seven-pass transmembrane receptors (GPCRs), allowing neutrophil 
arrest. Neutrophils that adhere to the vessel wall produce intravascular NETs, potentially with the contribution of activated platelets, probably through the binding of 
neutrophil LFA-1 with platelet ICAM-2 (?). DNA, histones, IL-17, active proteases, such as MPO, neutrophil elastase, and cathepsin G, released during NET 
formation, induce the production of pro-inflammatory cytokines and thrombin, contributing to the loss of blood–brain barrier integrity. Neutrophils inside the cerebral 
parenchyma are activated by inflammatory mediators potentially released by glial cells and produce NETs, which may further activate glial cells and harm 
surrounding neurons. NETs could, therefore, represent a mechanism of neutrophil-mediated intravascular and intraparenchymal tissue damage in AD.
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to Aβ peptides increases the expression of cytokine genes, 
including the gene encoding IL-1β, which induces NETosis 
(77). Aβ may further contribute to intravascular NETosis 
through its interaction with the receptor for advanced glycation 
end-products (RAGE) on brain endothelial cells, promoting 
the generation of ROS and the secretion of pro-inflammatory 
cytokines (19, 65, 78).
Several studies have shown that platelets exist in a pre-
activated state in the blood of an AD mouse model (APP23) and 
in human AD patients, showing strongly enhanced responses 
upon stimulation and potentially offering biomarkers for the 
early diagnosis of AD (79, 80). The exposure of platelets to 
Aβ induces platelet activation with the further production of 
Aβ and ROS, initiating a vicious circle that enhances vascular 
inflammation (81, 82). Activated platelets can also trigger the 
production of NETs, and in  vitro studies have demonstrated 
that adding platelets stimulated with agonists, such as ADP, 
collagen, thrombin, LTB4, or arachidonic acid to neutrophils 
causes NET formation (58, 83, 84). Intravascular NETs may 
be induced by activated platelets interacting with neutrophils 
via Toll-like receptor 4 (TLR4) or LFA-1 integrin, and we 
speculate that the release of intravascular NETs found in AD 
mouse models and human AD subjects could be promoted by 
activated platelets interacting with adherent neutrophils (56, 59, 
85). Interestingly, blocking LFA-1 integrin inhibits neutrophil 
adhesion in the brain microvasculature of AD mice, and LFA-1 
deficiency reduces the cognitive deficit and neuropathological 
changes in animal models of AD (8). However, it is unclear 
whether intravascular NETosis is less severe in AD mice lack-
ing LFA-1 integrin, and further studies are required to address 
this issue. Following activation, platelets present the high 
mobility group box 1 (HMGB1) protein to neutrophils, causing 
them to produce NETs (83). HMGB1 is a damage-associated 
molecular pattern (DAMP) released during apoptosis and is 
involved in leukocyte recruitment and local activation (86). It 
migrates from the cytoplasm to the surface following platelet 
activation and interacts with several receptors on the neutrophil 
surface including RAGE (87). RAGE has been shown to play an 
essential role in the production of NETs and the treatment of 
neutrophils with anti-RAGE antibodies prevents NET forma-
tion induced either by activated platelets or by recombinant 
HMGB1, suggesting that Aβ or HMGB1 inside vessels may 
interact with neutrophil RAGE leading to NET formation in AD 
(83). HMGB1 activates neutrophils, induces the production of 
pro-inflammatory cytokines and upregulates the expression of 
VCAM-1 and selectins on endothelial cells, potentially amplify-
ing the inflammatory responses in AD (87–90). HMGB1 also 
potentiates further NET formation by interacting with TLR4 
in a ROS-independent manner, contributing to tissue damage 
during sterile inflammation (91). We, therefore, hypothesize 
that the release of HMGB1 during the formation of NETs may 
exacerbate neuroinflammation and that HMGB1-targeted 
therapy may, therefore, be beneficial in neutrophil-associated 
inflammatory conditions, such that blocking the activity of this 
protein may also offer a new therapeutic approach to AD.
Intravascular NETosis promotes blood clotting, and NET 
release by activated neutrophils triggers both thrombin 
formation through the induction of prothrombinase activity and 
the aggregation of platelets (57, 92, 93). Indeed, during severe 
sepsis in liver sinusoids, intravascular NETs induce thrombus 
formation and the partial or total occlusion of capillaries (59). 
Thrombin expressed by endothelial cells enhances platelet 
activation, amplifying chronic inflammation and thrombus 
formation (94). Thrombin levels are elevated in the vessel walls 
and senile plaques of AD patients, and thrombin inhibitors can 
reduce vascular inflammation by limiting the cerebrovascular 
expression of inflammatory proteins and ameliorating cognitive 
functions in transgenic animal models of AD (71, 95). Thrombin 
formation triggered by NETosis may, therefore, exacerbate vas-
cular inflammation and neuronal injury in AD. Furthermore, 
NETs and IL-17 are important constituents of the fresh and lytic 
thrombus after acute myocardial infarction, and their specific co-
localization suggests that they may play a role during thrombus 
stabilization and growth (96). Platelets express the receptor for 
IL-17A and IL17-F (IL–17RA), and the incubation of platelets 
with IL-17A promotes their aggregation (97). Notably, elevated 
IL-17 serum levels have been reported in a cohort of Chinese 
AD patients, suggesting it may contribute to platelet activation 
during AD (98). Altogether, these findings suggest that the for-
mation of NETs together with IL-17 release by neutrophils may 
activate platelets and exacerbate brain microvessel pathology, 
contributing to the reduced brain perfusion and NVU alterations 
observed in AD (99).
Intravascular NETs can also damage the endothelial wall 
by releasing a mixture of nuclear proteins and proteases, NE, 
cathepsin G, and metalloproteinases (MMPs). Indeed, NE and 
MMPs may destroy tight junction components to promote 
endothelial cell injury (100). As recently reported in patients with 
SLE, the MMPs normally contained within neutrophil granules 
are externalized in NETs and can damage the integrity of the 
vascular wall, and MMP-9 in particular can activate endothelial 
MMP-2 and trigger apoptosis (101). In addition, NE increases 
endothelial permeability and the expression of ICAM-1 on 
endothelial cells and thus can damage the BBB (102). The most 
abundant proteins in NETs are MPO and histones, and these can 
also induce endothelial cell death (103, 104). These vasculopathic 
effects of NETs have been demonstrated in vivo by using protein 
arginine deiminase (PAD) inhibitors to prevent the formation of 
NETs, which protects against vascular damage and ameliorates 
the phenotype of SLE (105, 106). In AD mouse models, the 
expression of MMPs is induced whereas the expression of tight 
junction proteins is suppressed in microvessels near Aβ plaques 
in the brain (107). Furthermore, the treatment of the BBB with 
oligomeric Aβ1–42 in vitro increased its permeability and reduced 
the availability of tight junction scaffold proteins (108). MMP-2 
and MMP-9 released by endothelial cells stimulated with Aβ1–42 
contribute to Aβ-induced BBB leakage, so the MMPs externalized 
during NET formation may exacerbate tight junction damage 
and changes in BBB permeability induced by Aβ (108).
iNTRAPAReNCHYMAL NeTosis iN AD
Neutrophils invade the brain parenchyma of AD mouse models 
at the early stage of AD and contribute to the induction of 
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memory deficit (8, 32). We have recently shown that intraparen-
chymal migrating neutrophils produce NETs, showing the pres-
ence of cells releasing MPO, NE, and citrullinated histone H3 
in the parenchyma of mouse models of AD (8). Furthermore, 
we have also confirmed the formation of NETs in human AD 
subjects by the co-localization of MPO and citrullinated his-
tones, and of MPO and NE (8). These data suggest that NETs 
may represent a neutrophil-dependent disease mechanism in 
patients with AD (Figure 1).
Our recent TPLSM data indicate that a significant proportion 
of the intraparenchymal neutrophils are fully arrested, suggest-
ing the presence of activating stop signals for neutrophils inside 
the brains of mouse AD models. Neutrophils migrate inside the 
parenchyma in areas with Aβ plaques and less neuronal fluores-
cence, suggesting a role for Aβ in neutrophil migration inside 
the parenchyma and in providing stop signals for neutrophils. 
Aβ is included in the class of DAMP that are released following 
non-microbial tissue injury, alerting the innate immune system 
and activating a wide array of receptors and pro-inflammatory 
pathways (109).
Aβ promotes the generation of ROS by activating NADPH 
oxidase in both human and mouse neutrophils in  vitro, and 
several reports, including our own, have demonstrated that ROS 
production is a necessary step in the formation of NETs (5, 8, 
110). These data provide further support for the role of Aβ in 
intraparenchymal NET formation and neutrophil-dependent 
CNS damage during AD. Interestingly, a recent study demon-
strated that NET formation in human neutrophils in vitro is also 
driven by the fibrillary form of amyloids from other sources, such 
as α-synuclein, Sup35, and transthyretin (111). In the same study, 
the presence of NETs was observed near amyloid deposits in 
patients with systemic amyloidosis, and NET-associated elastase 
was able to degrade amyloid fibrils into short toxic oligomeric 
species, suggesting that amyloid fibrils act as a reservoir of toxic 
peptides that may promote amyloid disease pathogenesis. We, 
therefore, hypothesize that Aβ may trigger NET formation in the 
AD brain by binding to FPR1 or FPR-like-1 receptors on neu-
trophils, and the NETs may in turn promote the release of toxic 
Aβ species from amyloid plaques, amplifying the inflammatory 
network in AD.
Intraparenchymal cytokines, such as TNFα, IL-1β, and IL-8, 
produced by neural cells may also promote NET formation in 
extravasated neutrophils during AD (60). Indeed, our recent 
data suggest that interconnectivity between neutrophils and 
glial cells may create several feedback loops, amplifying and 
sustaining their reciprocal activation (Figure  1). Accordingly, 
activated astrocytes and microglia in AD patients secrete pro-
inflammatory cytokines, such IL-1β, TNFα, and IL-8, as well as 
ROS into the surrounding brain tissue rich in Aβ deposits, thus 
potentially contributing to intraparenchymal NET formation 
and generating crosstalk with intraparenchymal neutrophils 
(Figure 1) (12, 13, 17). Both TNFα and IL-1β have recently been 
implicated in NETosis in rheumatoid arthritis and gout, suggest-
ing they may contribute to NET formation also in AD (112, 113). 
Moreover, treatment with anakinra (a recombinant IL-1 receptor 
antagonist) or a monoclonal antibody that blocks IL-1β caused 
the partial inhibition of NET formation by neutrophils treated 
with synovial fluid from patients with gout, further supporting 
a role for IL-1β in the formation of NETs (112). Higher levels of 
IL-1β and TNFα are found in the brain and cerebrospinal fluid 
(CSF) of AD patients, suggesting these molecules may contribute 
to neutrophil activation and NET formation in AD (114, 115). 
IL-8 is abundant in the CSF of patients in the prodromal stage of 
AD and in the brains of AD subjects, suggesting this cytokine may 
attract neutrophils and contribute to NET formation in the AD 
brain (116). Our recent data showed that migrating neutrophils 
produce IL-17 in the cortex and hippocampus of 3xTg-AD mice 
(8). IL-17 is a cytotoxic cytokine for neurons and may contribute 
to the loss of BBB integrity and the recruitment of neutrophils 
in other inflammatory CNS diseases (117, 118). Furthermore, 
recent studies show that IL-17 contributes to NETosis in rheu-
matoid arthritis and in a model of acute myocardial infarction, 
suggesting this cytokine may favor NET formation also in AD 
(96, 113). These combined data suggest that pro-inflammatory 
cytokines may act in concert with Aβ and ROS to promote intra-
parenchymal NETosis in AD.
Intraparenchymal NETosis may be harmful to neural cells 
in AD through several mechanisms (Figure 1). Indeed, during 
the generation of NETs, the azurophilic granules of neutrophils 
release MMPs, in particular MMP-9, and serine proteases such 
as NE, cathepsin G, and MPO, which can induce tissue dam-
age and aggravate the inflammatory process. Neutrophils are 
equipped with high levels of MMP-9, stored as the inactive form 
pro-MMP-9. Recent data indicate that that Aβ25–35 induces 
the degranulation process following neutrophil activation and 
the massive secretion of the inactive pro-MMP-9 stored in 
cytoplasmic granules (119). After neutrophil stimulation, pro-
MMP-9 can be converted into active MMP-9 by several of the 
proteases released by activated neutrophils (including NE), or 
by Aβ-stimulated brain cells (119). MMPs are involved in the 
proteolysis of the extracellular matrix and can thus damage the 
brain parenchyma (120). NE can also induce the degradation 
of tissues not only by cleaving extracellular matrix proteins, 
such as elastin, collagen, and proteoglycan but also by activating 
MMPs and inactivating the endogenous tissue inhibitors of 
MMPs (TIMPs) (121). MPO localized within NETs also inacti-
vates TIMPs and thus indirectly enhances the local pathogenic 
activity of MMPs (122). TIMPs have been localized in neuritic 
senile plaques and NFTs in the hippocampus and cerebral cortex 
of human AD brains (123). Furthermore, MMP-9 is expressed in 
senile plaques, NFTs, and the vascular walls of human AD brains 
as well as in Aβ-stimulated astrocytes and activated microglia, 
and its inhibition is therapeutically beneficial in a transgenic 
mouse model of AD (124–127). The main constituents of NETs 
are histones (2). Each histone protein has an N-terminal tail 
with lysine and arginine residues that extend from the core. 
These residues can be modified by acetylation, methylation, and 
citrullination among others, and the latter is associated with 
PAD4, which plays a central role in the formation of NETs. 
In PAD4-knockout mice, the absence of histone citrullination 
prevents the decondensation of chromatin (64, 128). When 
translocated into the extracellular space, histones function as 
DAMP, amplifying the sterile inflammation state and show-
ing toxicity to the surrounding cells by activating TLRs and 
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inflammasome pathways (129, 130). During neurodegeneration 
in particular, extracellular histones can stimulate the innate 
immune response and induce apoptosis in neuronal cells. 
Indeed, a recent study has shown that extracellular histone 
H1 induces a pro-inflammatory response in microglia and 
causes neuronal death by activating the mitochondrial apoptosis 
pathway (131). In AD brains, extracellular histone H1 has been 
found within amyloid plaques due to its capacity to bind APP 
and β-amyloid with high affinity (132, 133). The accumulation 
of extracellular histones may, therefore, accelerate neurode-
generation and perpetuate the inflammatory process in AD.
FUTURe DiReCTiONS
NETosis aggravates several inflammatory and autoimmune 
disorders. The unexpected recent discovery that neutrophils 
promote AD pathogenesis in mouse models opened a new area 
of investigation highlighting the prominent role of circulating 
immune system cells in AD. The mechanisms of neutrophil-
dependent damage in AD are unclear, and the discovery of 
NETs in mouse models of AD and human AD patients indicates 
a potential mechanism that neutrophils may use to induce and 
exacerbate neuroinflammation, by promoting cerebral vascu-
lature dysfunction and parenchymal damage. However, the 
role of NET components in the induction and perpetuation of 
neuroinflammation in AD needs to be determined in more detail 
in further studies.
Neutrophils are key regulators of the immune system because 
these cells communicate and interact with adaptive immune 
system cells during infections and chronic inflammatory and 
autoimmune diseases (33, 134). NETs activate plasmacytoid 
dendritic cells through TLR9 during viral infections and autoim-
mune diseases and can mediate the priming of T cells, which 
requires NET–T cell contacts and T-cell receptor signaling 
(7, 134, 135). Adaptive immune system cells are encountered in 
the AD brain, and they may play a role in AD pathogenesis, but 
it is unclear whether NETs link the innate and adaptive immune 
responses in AD (21). NET components provide a source of 
autoantigens, which promote the production of autoantibodies 
and stimulate the immune system leading to tissue damage, 
but it is not known whether NETs are autoantibody targets and 
whether they generate AD biomarkers (4, 113). Citrullinated 
proteins in particular bind to autoantibodies, which in associa-
tion with pro-inflammatory cytokines perpetuate the formation 
of NETs (113, 136). The presence of citrullinated vimentin and 
histone H3 has been detected in the hippocampus and cerebral 
vessels of AD patients, but the role of such proteins in AD is 
currently unclear (8, 137).
The inhibition of NET formation could offer a novel thera-
peutic approach to limit the extensive damage caused during 
AD. Evidence from animal models and human AD patients 
suggests that the targeting of NET components, such as NADPH 
oxidase, PAD, and DNase I, may help to prevent NET extrusion 
and limit tissue damage (138). Indeed, NET-targeted therapy 
has shown beneficial effects in animal models of diseases, such 
as SLE, atherosclerosis, and rheumatoid arthritis (105, 113, 138, 
139). However, the effect of blocking NET formation in animal 
models of AD has not yet been demonstrated and further studies 
are required to determine whether this approach has merit. In 
conclusion, NETs represent a novel disease mechanism in AD, 
and targeting their effects during sterile inflammation may pro-
vide an additional therapeutic strategy for the treatment of this 
devastating disease.
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